DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC

Information source: University Health Network, Toronto
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatocellular Carcinoma

Intervention: CT perfusion (Radiation); Norepinephrine intra-arteriel/hepatic (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University Health Network, Toronto

Official(s) and/or principal investigator(s):
Dheeraj Rajan, MD FRCPC, Principal Investigator, Affiliation: University Health Network/Mount Sinai Hospital

Overall contact:
Maxime Noel-Lamy, MD FRCPC, Phone: 416-946-4501, Ext: 5054, Email: maxime.noel-lamy@uhn.ca

Summary

Dr Rajan is investigating a new method to improve local treatment of liver cancer. There is evidence that a drug, norepinephrine (NE), has the ability to shrink down normal liver blood vessels, but leave tumor vessels wide open. In patients with primary liver cancer, NE will be injected directly in the artery that nourishes the liver and the tumor. Real time blood flow will be measured using an advanced CT scanner to demonstrate the NE effect on blood vessels. If Dr Rajan's hypothesis is confirmed, this drug has great potential to benefit patients during local delivery of chemotherapy in the liver artery, diverting it away from normal liver and towards the tumor, resulting in less complications and improved tumor kill.

Clinical Details

Official title: Hepatic Arterial Blood Flow Modulation in Patients With Hepatocellular Carcinoma: Influence of Intra-arterial Norepinephrine Assessed With CT Perfusion

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Liver blood flow

Detailed description: This study aims to evaluate the blood flow modifications in liver following injection of norepinephrine in the hepatic artery. These blood flow variations have never been dynamically evaluated before. If indeed blood flow modulation in liver is favorable, the use of norepinephrine prior to localized chemotherapy has great potential to enhance treatment and diminish side effects. Patients with hepatocellular carcinoma, a primary liver cancer, will be selected for this study. Included patients will have a trans-arterial chemoembolization (TACE) procedure scheduled as treatment for their cancer. During their procedure, they will be brought to an advanced CT-scanner. CT perfusion imaging will be performed prior, and after the injection of the study drug in the liver artery. Patient's treatment will then be completed. Perfusion color maps will illustrate blood flow. Perfusion values will be correlated to see how the drug modulates blood flow in tumor and in normal liver.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Biopsy proven HCC< or confident diagnosis of HCC on multi-phasic CT or MRI

- Selection criteria for chemoembolization must be met, including adequate coagulation

profile and serum creatinine, patent portal vein, no severe contrast allergy, cirrhosis Child A or B.

- 5 or less untreated nodular hepatic tumors within the lobe to undergo

chemoembolization. Larger nodule must be equal or over 3 cm.

- Patient must be able to provide written, informed consent.

Exclusion Criteria:

- Symptoms or history of ischemic cardiac disease or arrhythmia

- Uncontrolled hypertension

- Pregnancy or desire to get pregnant

- Severe COPD, FEVS lower than 30%

- Prior documented hypersensitivity to norepinephrine

- Patients receiving MAO inhibitors, or anti-depressants of the triptyline or

imipramine types

Locations and Contacts

Maxime Noel-Lamy, MD FRCPC, Phone: 416-946-4501, Ext: 5054, Email: maxime.noel-lamy@uhn.ca

Toronto General Hospital, Toronto, Ontario M5G 2N2, Canada; Recruiting
Maxime Noel-Lamy, MD FRCPC, Phone: 416-946-4501, Ext: 5054, Email: maxime.noel-lamy@uhn.ca
Additional Information

Starting date: January 2015
Last updated: June 12, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017